EGFR and neoplasm: There are still a considerable number of patients who fail to benefit from immunotherapy due to factors such as programmed death-ligand 1 (PD-L1) expression [3], epidermal growth factor receptor (EGFR) mutation status [9], low tumor mutation burden (TMB) [6], high neutrophil-lymphocyte ratio(NLR) [7], or low body mass index (BMI) [8].